Ignyta Inc. (RXDX): Great Point Partners Reports New Stake

Page 5 of 10 – SEC Filing

CUSIP No. 451731103

13G

Page 5 of 9 Pages

Explanatory Note: This Schedule 13G is being filed to report
that on April 29, 2016, the reporting persons’ beneficial ownership exceeded 5%. Subsequently, as a result of the
exercise of an underwriter’s option to purchase shares of the issuer’s common stock, such beneficial ownership
has decreased to below 5%.

Item 1.
	(a)	Name of Issuer
		Ignyta, Inc.
	(b)	Address of Issuer’s Principal Executive Offices
		11111 Flintkote Avenue, San Diego, CA 92121
Item 2.
	(a)	Name of Person Filing
		Great Point Partners, LLC
		Dr. Jeffrey R. Jay, M.D.
		Mr. David Kroin
	The Reporting Persons have entered into a Joint Filing Agreement, dated May 9, 2016, a copy of which is filed with this Schedule 13G as Exhibit A, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.
	(b)	Address of Principal Business Office, or if none, Residence
		The address of the principal business office of each of the Reporting Persons is
		165 Mason Street, 3rd Floor
		Greenwich, CT 06830
	(c)	Citizenship
	Great Point Partners, LLC is a limited liability company organized under the laws of the State of Delaware. Dr. Jeffrey R. Jay, M.D. is a citizen of the United States. Mr. David Kroin is a citizen of the United States.
	(d)	Title of Class of Securities
		Common Stock
	(e)	CUSIP Number
		451731103
Item 3.	If this statement is filed pursuant to §240.13d-1(b) or 240.13d.2(b) or (c), check whether the person filing is a:
		Not Applicable.
	(a)	o	Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o)
	(b)	o	Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
	(c)	o	Insurance company as defined in Section 3(a)(19) of the Act (15. U.S.C. 78c).
	(d)	o	Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
	(e)	o	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).